Phospho-ADAM17 (T735) Antibody

How do researchers distinguish between phosphorylated and non-phosphorylated forms of ADAM17?

Researchers typically use phospho-specific antibodies that selectively recognize the phosphorylated T735 residue in ADAM17. These antibodies are designed against synthesized phosphopeptides that mimic the region surrounding T735. Commercial antibodies such as Rabbit Anti-phospho-ADAM17 (Thr735) are generated using KLH-conjugated synthetic phosphopeptides derived from human ADAM17 around the phosphorylation site (PQ(p-T)PG), located in the cytoplasmic region . These tools allow scientists to monitor the phosphorylation status of ADAM17 under various experimental conditions and to track changes in response to stimuli or inhibitors.

What applications are most suitable for phospho-ADAM17 (T735) antibodies?

Phospho-ADAM17 (T735) antibodies are versatile research tools that can be employed in multiple experimental techniques. Based on manufacturer specifications, these antibodies are suitable for Western blotting (WB), enzyme-linked immunosorbent assay (ELISA), immunohistochemistry on paraffin-embedded tissues (IHC-P) and frozen sections (IHC-F), and immunofluorescence (IF) . The recommended dilutions vary by application:

Researchers should note that paraffin sections typically require antigen retrieval steps for optimal results .

How should experiments be designed to study T735 phosphorylation in ADAM17 activation?

When investigating the role of T735 phosphorylation in ADAM17 activation, researchers should design rescue experiments using ADAM17-deficient cell lines. The approach used in key studies involved:

• Using Adam17−/− mouse embryonic fibroblasts (mEFs) or other ADAM17-deficient cell lines like M2 CHO cells.

• Transfecting these cells with wild-type ADAM17, phosphorylation-deficient mutant (T735A), phosphomimetic mutant (T735D), cytoplasmic domain-deleted ADAM17, or an inactive control (ADAM17-E>A).

• Co-transfecting with ADAM17 substrates (such as TGFα-AP or TNFα) to measure shedding activity.

• Stimulating cells with activators like IL-1β, anisomycin (p38 MAPK activator), or PMA.

• Measuring substrate release as an indicator of ADAM17 activity.

• Including inhibitor studies with compounds like SB203580 (p38 MAPK inhibitor) or BIM I (PKC inhibitor) .

This comprehensive approach allows for comparative analysis of how different ADAM17 variants respond to stimuli, providing insights into the role of T735 in enzyme regulation.

What controls are essential when working with phospho-ADAM17 (T735) antibodies?

When conducting experiments with phospho-ADAM17 (T735) antibodies, researchers should implement several crucial controls:

• Positive control: Cells treated with known inducers of T735 phosphorylation (e.g., IL-1β or anisomycin).

• Negative control:

  • Phosphatase-treated samples to eliminate phosphorylation

  • Adam17−/− cells or ADAM17-knockdown samples

  • T735A mutant-expressing cells that cannot be phosphorylated at this position

• Antibody specificity controls:

  • Peptide competition assays using the immunizing phosphopeptide

  • Comparison with total ADAM17 antibody staining

• Pathway inhibitor controls: Samples treated with SB203580 to inhibit p38 MAPK, which has been shown to block activation of both wild-type and T735A mutant ADAM17 .

These controls help validate specificity and ensure that observed signals genuinely represent phosphorylated ADAM17 at T735.

What are the known stimuli that regulate ADAM17 T735 phosphorylation?

Several stimuli have been investigated for their effects on ADAM17 T735 phosphorylation and activation. The primary ones include:

• IL-1β: This pro-inflammatory cytokine has been studied for its ability to activate ADAM17 and potentially stimulate T735 phosphorylation, though research findings are contradictory regarding the necessity of T735 phosphorylation for activation .

• Anisomycin: An activator of the p38 MAP kinase pathway that has been used to study ADAM17 activation. Studies have shown that anisomycin can stimulate ADAM17 activity in both wild-type and T735A mutant forms of the enzyme .

• PMA (phorbol 12-myristate 13-acetate): A PKC activator that stimulates ADAM17 through a mechanism distinct from IL-1β and anisomycin. Research has shown that PKC inhibitor BIM I blocks PMA-stimulated shedding but not IL-1β or anisomycin-dependent stimulation, suggesting different activation pathways .

These stimuli provide valuable tools for dissecting the different regulatory mechanisms governing ADAM17 activity.

How do researchers address contradictions in the literature regarding T735 phosphorylation?

The scientific literature contains contradictory findings regarding the importance of T735 phosphorylation for ADAM17 activation. To address these contradictions, researchers should:

• Employ multiple cell systems: Test hypotheses in different ADAM17-deficient cell lines, as was done with Adam17−/− mEFs, M2 CHO cells, and primary mouse chondrocytes .

• Use multiple substrates: Evaluate ADAM17 activity using different substrates (e.g., TGFα-AP and TNFα) to ensure consistency across different readouts .

• Compare species variants: Test both human and mouse ADAM17 to determine if species differences explain conflicting results. Some studies specifically addressed this by performing rescue experiments with human ADAM17 and human ADAM17-T735A in mouse Adam17−/− cells .

• Assess multiple activation pathways: Compare activation by different stimuli (IL-1β, anisomycin, PMA) to determine if T735 phosphorylation is important for specific activation pathways but not others .

• Employ both tagged and untagged constructs: Test whether tags (e.g., HA-tag) affect regulation, as was done in studies showing comparable results with HA-tagged and untagged ADAM17 variants .

These rigorous approaches help isolate variables that might explain seemingly contradictory results in different experimental systems.

What molecular mechanisms have been proposed for ADAM17 activation independent of T735 phosphorylation?

Given that mutation of T735 or deletion of the cytoplasmic domain doesn't significantly affect ADAM17 activation by IL-1β or anisomycin, several alternative mechanisms have been proposed:

The fact that p38 MAPK inhibitor SB203580 blocks activation of both wild-type and cytoplasmic tail-deficient ADAM17 suggests that while p38 MAPK is required for activation, it likely acts through mechanisms other than direct T735 phosphorylation .

How can researchers quantitatively assess changes in T735 phosphorylation?

To quantitatively measure changes in ADAM17 T735 phosphorylation, researchers should employ multiple complementary techniques:

• Western blotting: Use phospho-specific antibodies to detect T735-phosphorylated ADAM17, with normalization to total ADAM17 levels. This approach allows for semi-quantitative assessment of phosphorylation status under different conditions.

• Phospho-proteomics: Mass spectrometry-based approaches can identify and quantify phosphorylation at T735 and potentially discover other phosphorylation sites that might compensate for or interact with T735.

• ELISA-based methods: Develop sandwich ELISA using capture antibodies against ADAM17 and detection with phospho-T735 specific antibodies for high-throughput quantification.

• Functional correlation: Correlate measured phosphorylation levels with functional readouts such as substrate shedding assays to establish dose-response relationships.

• Phosphorylation kinetics: Time-course experiments to track phosphorylation changes following stimulation, which can provide insights into the temporal relationship between phosphorylation and activation.

For optimal quantification, signal normalization to loading controls and total ADAM17 expression is essential, especially when comparing different ADAM17 variants or treatment conditions.

What are common technical challenges when detecting phospho-ADAM17 (T735)?

Researchers frequently encounter several technical challenges when working with phospho-ADAM17 (T735) antibodies:

• Low abundance of phosphorylated form: The phosphorylated form of ADAM17 may represent only a small fraction of the total ADAM17 pool, making detection challenging without enrichment strategies.

• Antibody specificity: Phospho-specific antibodies may exhibit cross-reactivity with similar phosphorylated motifs in other proteins, requiring careful validation.

• Sample preparation issues: Phosphorylation can be lost during sample preparation due to phosphatase activity, necessitating phosphatase inhibitors in all buffers.

• Detection of mature versus pro-form: Overexpressed ADAM17 is mainly detected as a pro-form on Western blots, which may complicate interpretation of functional studies since the mature form is responsible for catalytic activity .

• Cellular localization: ADAM17 is predominantly located in the cell membrane, which can present extraction and solubilization challenges for biochemical analyses .

To address these challenges, researchers should optimize lysis conditions, include appropriate phosphatase inhibitors, employ enrichment strategies when necessary, and validate antibody specificity through appropriate controls.

How can phospho-ADAM17 (T735) antibodies be validated for experimental use?

Rigorous validation of phospho-ADAM17 (T735) antibodies is crucial for reliable experimental results. The validation process should include:

• Phosphatase treatment control: Treating samples with lambda phosphatase should eliminate the signal if the antibody is truly phospho-specific.

• Mutant expression systems: Testing antibody reactivity in cells expressing T735A mutant ADAM17 should show no signal compared to wild-type ADAM17.

• Peptide competition assays: Pre-incubation of the antibody with phosphorylated and non-phosphorylated peptides corresponding to the T735 region should selectively block binding to the phosphorylated peptide.

• Stimulus-response validation: Confirming increased antibody reactivity after treatment with stimuli known to activate relevant kinase pathways (such as IL-1β or anisomycin).

• Cross-species reactivity assessment: Testing the antibody against ADAM17 from different species to confirm the predicted reactivity pattern. Most phospho-ADAM17 (T735) antibodies are reactive with human and mouse ADAM17, with predicted reactivity to rat, pig, cow, and sheep variants .

Thorough validation ensures that experimental observations genuinely reflect changes in T735 phosphorylation rather than artifacts or non-specific binding.

What functional assays best complement phospho-ADAM17 (T735) antibody experiments?

To establish meaningful correlations between T735 phosphorylation and ADAM17 function, researchers should employ complementary functional assays:

• Substrate shedding assays: Measure release of ADAM17 substrates such as:

  • TGFα-AP (alkaline phosphatase-tagged transforming growth factor alpha)

  • TNFα (using ELISA for quantification)

  • Other EGFR ligands

• Rescue experiments: Introduction of wild-type or mutant ADAM17 into ADAM17-deficient cells (Adam17−/− mEFs, M2 CHO cells) to assess functional rescue capacity .

• Inhibitor studies: Treatment with:

  • SB203580 (p38 MAPK inhibitor)

  • BIM I (PKC inhibitor)
    to dissect signaling pathways involved in ADAM17 regulation .

• Mutation analysis: Compare activity of:

  • Wild-type ADAM17

  • T735A (phosphorylation-deficient mutant)

  • T735D (phosphomimetic mutant)

  • Cytoplasmic domain deletion mutants
    to determine the functional significance of T735 phosphorylation .

• Cell-based protease activity assays: Using fluorogenic substrates to measure ADAM17 activity in intact cells or membrane preparations.

These functional assays provide critical context for interpreting changes in T735 phosphorylation status and help establish or refute causal relationships between phosphorylation and activation.

What are the promising research avenues for understanding ADAM17 regulation beyond T735 phosphorylation?

Given the contradictory findings regarding T735 phosphorylation, several alternative research directions warrant investigation:

• Extracellular domain regulation: Focusing on conformational changes in the extracellular domains, particularly the cysteine-rich domain, which has been implicated in ADAM17 regulation through the C600Y mutation study .

• Membrane microenvironment: Investigating how changes in lipid composition, membrane fluidity, or compartmentalization affect ADAM17 activity independent of cytoplasmic signaling.

• Substrate-specific regulation: Exploring whether different ADAM17 substrates are regulated through distinct mechanisms, potentially explaining some of the contradictory results in the literature.

• Proteomic approaches: Identifying ADAM17-interacting proteins that may mediate activation in response to different stimuli, potentially bypassing the need for direct cytoplasmic phosphorylation.

• Post-translational modifications beyond phosphorylation: Investigating other modifications such as ubiquitination, SUMOylation, or glycosylation that might regulate ADAM17 activity.

These research directions may provide new insights into the complex regulation of ADAM17 that cannot be explained solely by T735 phosphorylation.

How might phospho-ADAM17 (T735) antibodies contribute to understanding inflammatory disease mechanisms?

ADAM17 plays a critical role in inflammatory processes through its regulation of TNFα and EGFR ligand shedding. Phospho-specific antibodies can contribute to understanding inflammatory disease mechanisms in several ways:

• Biomarker development: Assessing whether T735 phosphorylation status correlates with disease activity in inflammatory conditions associated with ADAM17 dysfunction, such as inflammatory skin and bowel disease .

• Therapeutic target validation: Determining whether modulation of T735 phosphorylation affects disease-relevant ADAM17 substrates differently from total ADAM17 inhibition, potentially offering more selective therapeutic approaches.

• Pathway cross-talk analysis: Investigating how inflammatory signaling pathways that activate p38 MAPK intersect with ADAM17 regulation in disease contexts, potentially revealing new intervention points.

• Cell-type specific regulation: Examining whether T735 phosphorylation has differential importance across cell types involved in inflammatory diseases, potentially explaining tissue-specific manifestations.

• Temporal regulation during disease progression: Tracking changes in T735 phosphorylation status throughout disease progression to identify critical windows for therapeutic intervention.

These applications could advance our understanding of ADAM17's role in inflammatory pathologies and potentially lead to more targeted therapeutic strategies.